Light in and sound out: emerging translational strategies for photoacoustic imaging
S Zackrisson, S Van De Ven, SS Gambhir - Cancer research, 2014 - AACR
Photoacoustic imaging (PAI) has the potential for real-time molecular imaging at high
resolution and deep inside the tissue, using nonionizing radiation and not necessarily …
resolution and deep inside the tissue, using nonionizing radiation and not necessarily …
Current status of brachytherapy in cancer treatment–short overview
J Skowronek - Journal of contemporary brachytherapy, 2017 - termedia.pl
Purpose Brachytherapy, as a definition, is derived from ancient Greek words for 'short
distance'(brachios) and 'treatment'(therapy), and refers to therapeutic use of encapsulated …
distance'(brachios) and 'treatment'(therapy), and refers to therapeutic use of encapsulated …
[HTML][HTML] GEC/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: an update
Background: HDR afterloading brachytherapy (HDRBT) for prostate cancer is now
established as an effective technique to achieve dose escalation in the radical treatment of …
established as an effective technique to achieve dose escalation in the radical treatment of …
The evolution of brachytherapy for prostate cancer
Abstract Brachytherapy (BT), using low-dose-rate (LDR) permanent seed implantation or
high-dose-rate (HDR) temporary source implantation, is an acceptable treatment option for …
high-dose-rate (HDR) temporary source implantation, is an acceptable treatment option for …
[HTML][HTML] The effects of ionising and non-ionising electromagnetic radiation on extracellular matrix proteins
Exposure to sub-lethal doses of ionising and non-ionising electromagnetic radiation can
impact human health and well-being as a consequence of, for example, the side effects of …
impact human health and well-being as a consequence of, for example, the side effects of …
[HTML][HTML] Radioactive iodine-125 in tumor therapy: advances and future directions
S Wei, C Li, M Li, Y Xiong, Y Jiang, H Sun, B Qiu… - Frontiers in …, 2021 - frontiersin.org
Radioactive iodine-125 (I-125) is the most widely used radioactive sealed source for
interstitial permanent brachytherapy (BT). BT has the exceptional ability to deliver extremely …
interstitial permanent brachytherapy (BT). BT has the exceptional ability to deliver extremely …
Effect of dataset size, image quality, and image type on deep learning-based automatic prostate segmentation in 3D ultrasound
Abstract Three-dimensional (3D) transrectal ultrasound (TRUS) is utilized in prostate cancer
diagnosis and treatment, necessitating time-consuming manual prostate segmentation. We …
diagnosis and treatment, necessitating time-consuming manual prostate segmentation. We …
[HTML][HTML] High dose-rate brachytherapy in the treatment of prostate cancer
LC Mendez, GC Morton - Translational andrology and urology, 2018 - ncbi.nlm.nih.gov
High dose-rate (HDR) brachytherapy involves delivery of a high dose of radiation to the
cancer with great sparing of surrounding organs at risk. Prostate cancer is thought to be …
cancer with great sparing of surrounding organs at risk. Prostate cancer is thought to be …
Automatic multi‐catheter detection using deeply supervised convolutional neural network in MRI‐guided HDR prostate brachytherapy
Purpose High‐dose‐rate (HDR) brachytherapy is an established technique to be used as
monotherapy option or focal boost in conjunction with external beam radiation therapy …
monotherapy option or focal boost in conjunction with external beam radiation therapy …
Five-year outcomes of a single-institution prospective trial of 19-Gy single-fraction high-dose-rate brachytherapy for low-and intermediate-risk prostate cancer
ZA Siddiqui, GS Gustafson, H Ye, AA Martinez… - International Journal of …, 2019 - Elsevier
Purpose To update outcome and toxicity results of a prospective trial of 19-Gy single-fraction
high-dose-rate (HDR) brachytherapy for men with low-and intermediate-risk prostate cancer …
high-dose-rate (HDR) brachytherapy for men with low-and intermediate-risk prostate cancer …